Audit: QRS - Calcium Alpha-Ketoglutarate for Health & Longevity

Audit conducted on 07/09/2026 07:14 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every cell, gate item, tier item and table row traces to a literal ER passage; spot-checked across Protocol, Time to Effect, Benefits, Risks, Monitoring and Qualitative Assessment.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious ER phrasing carried verbatim: “No symptomatic effect should be expected” (time_1_sub) and “No chronobiology data exist” (action_2_sub).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Thresholds and severity preserved, e.g. “outside nephrology supervision” and “Digoxin, without cardiology oversight”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid” list plus the Digoxin interaction; no Benefit- or Risk-Modifying Factor is relabelled as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only “Rejuvant” and “the ABLE trial” appear, both named in the ER for the same dosing fact; no PMIDs or NCT identifiers are introduced.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears that is absent from the ER.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, sceptical register and its British spelling (hypercalcaemia, signalling, ageing).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven while remaining accessible; the At-A-Glance closes on an actionable, non-alarmist framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as evidence and standard practice rather than instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No advisory verbs; the only clinician reference is the fixed template disclaimer.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Uses presentational phrasing such as “Common consumer practice” and “Standard practice” rather than recommending.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the rendered text.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language throughout; the clinical terms retained are unavoidable decision-gate names taken from the ER.
2.8	Information is presented in a concise and very compact manner	🟢	All content is compressed to short noun phrases and semicolon-separated lists.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framed for a risk-aware adult running biomarker monitoring and a multi-year protocol.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Ten-marker monitoring panel and a multi-year cadence assume a willing, effortful reader.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not pitched at a general population; assumes lab access and protocol adherence.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance states “Anyone tracking blood work and capping total calcium faces modest exposure”, the audience-specific weighting.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” is used throughout; “anti-aging” appears nowhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology used throughout (e.g. “gastrointestinal intolerance”, “adverse signal”).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and table column headers are byte-identical to the template.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables are present; marker_#* and qualitative_item# are expanded to the repeated rows the template defines.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A full structural diff against [qrs_template] shows changes confined to variable substitution; all other markup, comments and CSS are unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No section of the source ER is empty, so no empty-state phrasing applies. The empty Risks/High tier is governed by 13.5, not by this item.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol cell labels are verbatim ER bold labels (“Standard protocol”, “Best time of day”, “Single versus split dosing”); Monitoring row labels track the ER biomarker table.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Labels are taken from the ER; only non-decision-relevant glosses were trimmed under the section 8/9 concision rules.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No 🟩 / 🟥 / 🟨 or any other emoji occurs in the document body.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed at item level to its key fact; no section is expanded beyond its budget and no content spills into a second sheet.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment is the first element after <!doctype html> (lines 2–14).
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML is delimited by --- at lines 3 and 13; the preamble text sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; not surfaced anywhere on the sheet.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:04" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: calcium_alpha_ketoglutarate_2026-0907-0235_Opus_ER.md matches the source ER.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 matches the version of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0907-0657 is in YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number only.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	No stray whitespace or unnecessary quoting in any value.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &)	🟢	<title>Calcium Alpha-Ketoglutarate for Health &amp; Longevity - Quick Reference Sheet</title> with the ampersand correctly entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &)	🟢	header_topic matches canonical_topic with &amp; encoding.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Creation date 2026-0907-0657 renders as 09/07/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	header_subline_model is “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	No badge, version stamp, alternate-names line or audit date was added to the header.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Distils the ER Conclusion into origin, best-evidenced uses, the weakness of the longevity case, and the exposure verdict.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the four sentences maps to a distinct Conclusion passage.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Plain-language throughout; no acronyms or specialist classifications.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year or sample size; the null replication is referred to only as “a large independent programme”.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, relative risks or statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Derived from the ER Key Interactions & Contraindications section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER “Populations who should avoid” bullets plus the Digoxin absolute contraindication are represented.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	All nine items are <li></li> elements.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale stripped, including the em-dash clause on granulomatous disease and the “on absence of any safety data” clause on pregnancy.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Thresholds retained: “above 10.5 mg/dL”, “below 30 mL/min/1.73 m²”, “two or more calcium stones in five years”, “stage 4 or 5”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names eight avoid-populations plus one absolute contraindication, and all are carried through.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty; nine contraindication items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Derived from the ER Key Interactions & Contraindications section.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine remaining ER interaction bullets are present; Digoxin is correctly excluded and placed under Contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	All nine items are <li></li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Severity, consequence and mitigation clauses are stripped; only the agent or class remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved for tetracyclines/fluoroquinolones, bisphosphonates, thiazides, iron salts, AKG salts and growth-pathway suppressors.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions and all are carried through.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty; nine interaction items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Derived from the ER Therapeutic Protocol section.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard dose, timing and split-versus-single dosing are the three decision-relevant aspects; the competing-approach and modifier bullets are correctly not promoted.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section supplies three or more distinct actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action fields carry ER-derived content.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Serum phosphate, bone-breakdown marker and biological age are the three time-anchored readouts the ER quantifies.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High (phosphate, 4 weeks) → Medium (bone marker, 12 weeks) → Speculative (biological age, 7 months), matching benefit magnitude.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields carry ER-derived content, with 4 weeks, 12 weeks and 7 months all traceable to ER text.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (Practical Considerations and the benefit magnitudes), so the row is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Derived from the ER Expected Benefits section.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four tier variables are populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is reduced to a bare noun phrase; no magnitudes, p-values or study details carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content remains in any tier.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers (high, medium, low, speculative) carry items in the ER, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Derived from the ER Potential Risks & Side Effects section.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four tier variables are addressed.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is a bare noun phrase; the ER’s frequencies, hazard ratios and confidence intervals are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content remains in any tier.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No risk reaches High”, and risks_high carries style="display: none" with no empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success section.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarker-table rows are present in order with their optimal ranges intact.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated with the ER’s six-week / six-month / annual cadence plus the urinary calcium and epigenetic clock intervals.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success section.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers are listed.

Issues 07/09/2026 07:14

Pass rate 100.00%. No issues found.

Issues 07/09/2026 07:04

1. 4.5 — Sheet overflows one A4 page: At the template’s print geometry (~1030 px usable height on A4) the populated sheet runs to roughly 1,900 px, driven by the ~480 px Monitoring card, the ~370 px decision gates and multi-line cells such as benefits_speculative (lines 556–564), the CKD contraindication (lines 581–584) and action_3_sub (lines 483–486), none of which are condensed to their per-section budget.

Fixes 07/09/2026 07:04

1. 4.5 — Benefits tier condensed: Trimmed benefits_speculative from eight fully-worded items to their key facts (“Lower epigenetic age estimates” → “Lower epigenetic age”, “preservation of ovarian reserve and egg quality” → “ovarian reserve and egg quality”), removing a rendered line.
2. 4.5 — Contraindication items shortened: Cut the hypercalcaemia, nephrolithiasis and chronic-kidney-disease gates to their thresholds and staging (“estimated glomerular filtration rate below 30 mL/min/1.73 m²” → “below 30 mL/min/1.73 m²”), preserving every qualifier required by 8.5.
3. 4.5 — Key-interaction items shortened: Dropped redundant “Over-the-counter” prefixes and reduced “Other longevity interventions that suppress the growth pathway” to “Growth-pathway suppressors”, keeping all example-drug lists required by 9.5.
4. 4.5 — Protocol and time-to-effect subtexts tightened: Rewrote action_2_sub, action_3_sub, time_1_sub and time_2_sub to shorter equivalents with unchanged meaning.
5. 4.5 — Monitoring cells compacted: Shortened seven “Why” cells and two “Target” cells (e.g. “Governs how much added calcium is absorbed” → “Governs calcium absorption”, “No established target; track change against own baseline” → “No target; track own baseline”) so most table rows fall to a single line; all ten biomarkers retained per 14.2.
6. 4.5 — Monitoring cadence and qualitative items trimmed: Removed filler from monitoring_cadence and stripped trailing rationale from the first three qualitative items; all five markers retained per 15.2.